CN110891614A - Igf-1r单克隆抗体及其用途 - Google Patents
Igf-1r单克隆抗体及其用途 Download PDFInfo
- Publication number
- CN110891614A CN110891614A CN201880039129.XA CN201880039129A CN110891614A CN 110891614 A CN110891614 A CN 110891614A CN 201880039129 A CN201880039129 A CN 201880039129A CN 110891614 A CN110891614 A CN 110891614A
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Abstract
Description
原始残基 | 示例性取代 | 保守取代 |
Ala (A) | Val、Leu、Ile | Val |
Arg (R) | Lys、Gln、Asn | Lys |
Asn (N) | Gln、His、Lys、Arg | Gln |
Asp (D) | Glu | Glu |
Cys (C) | Ser | Ser |
Gln (Q) | Asn | Asn |
Glu (E) | Asp | Asp |
Gly (G) | Pro | Pro |
His (H) | Asn、Gln、Lys、Arg | Arg |
Ile (I) | Leu、Val、Met、Ala、Phe、正亮氨酸 | Leu |
Leu (L) | 正亮氨酸、Ile、Val、Met、Ala、Phe | Ile |
Lys (K) | Arg、Gln、Asn | Arg |
Met (M) | Leu、Phe、Ile | Leu |
Phe (F) | Leu、Val、Ile、Ala | Leu |
Pro (P) | Gly | Gly |
Ser (S) | Thr | Thr |
Thr (T) | Ser | Ser |
Trp (W) | Tyr | Tyr |
Tyr (Y) | Trp、Phe、Thr、Ser | Phe |
Val (V) | Ile、Leu、Met、Phe、Ala、正亮氨酸 | Leu |
Claims (32)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762502288P | 2017-05-05 | 2017-05-05 | |
US62/502288 | 2017-05-05 | ||
US201762545945P | 2017-08-15 | 2017-08-15 | |
US62/545945 | 2017-08-15 | ||
PCT/US2018/031233 WO2018204872A2 (en) | 2017-05-05 | 2018-05-04 | Igf-1r monoclonal antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110891614A true CN110891614A (zh) | 2020-03-17 |
Family
ID=64016737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880039129.XA Pending CN110891614A (zh) | 2017-05-05 | 2018-05-04 | Igf-1r单克隆抗体及其用途 |
Country Status (13)
Country | Link |
---|---|
US (2) | US11433148B2 (zh) |
EP (1) | EP3638320A4 (zh) |
JP (2) | JP7191938B2 (zh) |
KR (1) | KR20200004861A (zh) |
CN (1) | CN110891614A (zh) |
AU (1) | AU2018261890A1 (zh) |
BR (1) | BR112019023249A8 (zh) |
CA (1) | CA3062538A1 (zh) |
CL (1) | CL2019003169A1 (zh) |
MA (1) | MA49398A (zh) |
RU (1) | RU2019139434A (zh) |
WO (1) | WO2018204872A2 (zh) |
ZA (1) | ZA201908072B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA51103A (fr) | 2017-12-06 | 2020-10-14 | Avidity Biosciences Inc | Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique |
PE20211961A1 (es) * | 2018-12-03 | 2021-10-04 | Fusion Pharmaceuticals Inc | Terapia de combinacion de radioinmunoconjugados con inhibidores de danos y reparaciones del adn |
IL292133A (en) * | 2019-10-18 | 2022-06-01 | Nihon Mediphysics Co Ltd | Humanized antibody labeled with a radioactive isotope |
AU2021206233A1 (en) * | 2020-01-10 | 2022-08-11 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
CN115243729A (zh) * | 2020-01-10 | 2022-10-25 | 融合制药公司 | 大环螯合物及其用途 |
EP4126066A4 (en) | 2020-03-27 | 2024-04-24 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHY |
CA3233733A1 (en) * | 2021-09-29 | 2023-04-06 | National Research Council Of Canada | Egfrviii-targeted compounds and uses thereof |
WO2023070202A1 (en) * | 2021-10-25 | 2023-05-04 | Fusion Pharmaceuticals Inc. | Claudin 18.2-targeted compounds and uses thereof |
AU2022379928A1 (en) * | 2021-11-02 | 2024-05-09 | Fusion Pharmaceuticals Inc. | Methods of treating cancer |
WO2024044552A1 (en) * | 2022-08-22 | 2024-02-29 | Abdera Therapeutics Inc. | Vhh antibody dota conjugates |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1822861A (zh) * | 2003-07-24 | 2006-08-23 | 伯拉考成像股份公司 | 稳定的放射性药物组合物及制备方法 |
US20120213781A1 (en) * | 2011-02-11 | 2012-08-23 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
US20150056191A1 (en) * | 2012-03-30 | 2015-02-26 | Merck Sharp & Dohme Corp. | Igf1 biomarker for igf1r inhibitor therapy |
WO2015073575A2 (en) * | 2013-11-12 | 2015-05-21 | Centre For Probe Development And Commercialization | Residualizing linkers and uses thereof |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175343A (en) | 1985-01-14 | 1992-12-29 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US4889931A (en) | 1988-09-27 | 1989-12-26 | Salutar, Inc. | Manganese (II) chelate manufacture |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE69024826T2 (de) | 1989-02-10 | 1996-06-27 | Celltech Therapeutics Ltd | Aza-Macrozyklen und Verfahren zu deren Herstellung |
US5053503A (en) | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
US6274713B1 (en) | 1989-04-07 | 2001-08-14 | Salutar, Inc. | Polychelants |
US7385041B2 (en) | 1990-04-25 | 2008-06-10 | Bracco International B.V. | Dual functioning excipient for metal chelate contrast agents |
BR9102490A (pt) | 1990-06-18 | 1992-01-21 | Dow Chemical Co | Metodo para uso diagnostico na formacao de imagens e composicao |
US5386011A (en) | 1990-12-27 | 1995-01-31 | Abbott Laboratories | Hexapeptide anaphylatoxin-receptor ligands |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
CA2134239C (en) | 1992-06-09 | 2004-11-23 | Donald B. Axworthy | Pretargeting methods and compounds |
US5358704A (en) | 1993-09-30 | 1994-10-25 | Bristol-Myers Squibb | Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents |
GB9504922D0 (en) | 1995-03-10 | 1995-04-26 | Nycomed As | Process |
JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
IT1291624B1 (it) | 1997-04-18 | 1999-01-11 | Bracco Spa | Chelati complessi di metalli paramagnetici a bassa tossicita' |
IT1304501B1 (it) | 1998-12-23 | 2001-03-19 | Bracco Spa | Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza |
CA2371728C (en) | 1999-06-11 | 2009-06-02 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
DE10002939C1 (de) | 2000-01-13 | 2001-09-20 | Schering Ag | Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln |
US20020052354A1 (en) | 2000-01-27 | 2002-05-02 | Schering Ag | Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction |
US6264966B1 (en) | 2000-02-22 | 2001-07-24 | Concat, Ltd. | Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury |
DE60104421T2 (de) | 2000-05-12 | 2005-09-22 | University Hospital | Prochelators von radiometall markierten molekülen |
WO2002062398A2 (en) | 2001-01-08 | 2002-08-15 | Neorx Corporation | Radioactively labelled conjugates of phosphonates |
DE10135355C1 (de) | 2001-07-20 | 2003-04-17 | Schering Ag | Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie |
DE10135356C1 (de) | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
TWI240632B (en) | 2001-07-30 | 2005-10-01 | Epix Medical Inc | Purified peptides for peptide-based multimeric targeted contrast agents |
WO2004013161A2 (en) | 2002-08-06 | 2004-02-12 | Epix Pharmaceuticals, Inc. | Peptide aggregates |
DE10250870A1 (de) | 2002-10-31 | 2004-05-13 | Switch Biotech Ag | Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung |
WO2004071535A1 (en) | 2003-02-13 | 2004-08-26 | Bracco Imaging S.P.A. | Contrast enhanced x-ray phase imaging |
JP2007527366A (ja) | 2003-03-19 | 2007-09-27 | ウニヴェルズィテーツシュピタール・バーゼル | 癌診断および処置のための放射性医薬品 |
EP1641495A4 (en) | 2003-05-23 | 2009-02-25 | Epix Pharm Inc | OPTICALLY PURE AND ENRICHED ISOMERS OF CHEATING LIGANDS AND CONTRASTANTS |
JP4262545B2 (ja) | 2003-07-09 | 2009-05-13 | 三菱電機株式会社 | カスコード接続回路及びその集積回路 |
JP2007505315A (ja) | 2003-09-12 | 2007-03-08 | インヴィトロジェン コーポレーション | 多重結合および活性アッセイ |
PL380665A1 (pl) | 2003-12-19 | 2007-03-05 | Schering Corporation | Farmaceutyczne kompozycje |
WO2005079803A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
WO2006015318A2 (en) | 2004-07-30 | 2006-02-09 | Biogen Idec Inc. | Antibody conjugated to a drug moiety via a poptidic linker |
SI1791565T1 (sl) | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
US20060222595A1 (en) | 2005-03-31 | 2006-10-05 | Priyabrata Mukherjee | Nanoparticles for therapeutic and diagnostic applications |
WO2007009637A2 (de) | 2005-07-15 | 2007-01-25 | Bayer Schering Pharma Aktiengesellschaft | Deren verwendung als kontrastmittel zur anwendung in der nmr-, rontgen- und radiodiagnostik sowie in der radiotheraphie |
US7618957B2 (en) | 2005-07-15 | 2009-11-17 | Bayer Schering Pharma Aktiengesellschaft | Perfluoroalkyl-containing complexes, process for their production as well as their use |
US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
US20080058636A1 (en) | 2005-12-29 | 2008-03-06 | Epix Pharmaceuticals, Inc. | Methods of myocardial imaging |
EP1993613A2 (en) | 2006-03-15 | 2008-11-26 | Mallinckrodt, Inc. | Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
US7777029B2 (en) | 2006-05-02 | 2010-08-17 | San Diego State University (Sdsu) Foundation | Bifunctional chelators for sequestering lanthanides |
JP2010500417A (ja) | 2006-08-11 | 2010-01-07 | ライフ テクノロジーズ コーポレーション | センサータンパク質及びアッセイ方法 |
US8691761B2 (en) | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
GB0624587D0 (en) | 2006-12-08 | 2007-01-17 | Univ Muenchen Tech | Chelating agent |
US20100111858A1 (en) | 2007-01-19 | 2010-05-06 | Howard Carol P | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands |
WO2008134289A2 (en) | 2007-04-26 | 2008-11-06 | Mallinckrodt Inc. | High relaxivity coordinatively unsaturated lanthanide complexes |
ES2676598T3 (es) | 2007-08-27 | 2018-07-23 | Liebel-Flarsheim Company Llc | Eliminación de sílice a partir de compuestos hidrosolubles mediante nanofiltración y cromatografía en fase inversa |
WO2009032145A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
DE102008045937B4 (de) | 2008-04-11 | 2017-01-26 | Johannes-Gutenberg-Universität Mainz | Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons |
WO2010009246A2 (en) | 2008-07-16 | 2010-01-21 | The General Hospital Corporation | Methods and reagents for preparing multifunctional probes |
EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
US20110319339A1 (en) | 2008-11-06 | 2011-12-29 | Luisa Bracci | Neurotensin-derived branched peptides and uses thereof |
WO2010088527A2 (en) | 2009-01-30 | 2010-08-05 | Mayo Foundation For Medical Education And Research | Peptides and nanoparticles for therapeutic and diagnostic applications |
KR20110139274A (ko) | 2009-03-19 | 2011-12-28 | 와이어쓰 엘엘씨 | [2-(8,9-다이옥소-2,6-다이아자바이사이클로[5.2.0]논-1(7)-엔-2-일)에틸]포스폰산 및 이의 전구체의 제조 방법 |
WO2011005609A2 (en) | 2009-07-08 | 2011-01-13 | Mayo Foundation For Medical Education And Research | Imaging gastrointestinal volumes and motility |
WO2011079315A1 (en) | 2009-12-23 | 2011-06-30 | The Scripps Research Institute | Tyrosine bioconjugation through aqueous ene-like reactions |
WO2011090492A1 (en) | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
EP2397466B1 (en) | 2010-06-15 | 2012-11-28 | Centre National De La Recherche Scientifique CNRS | X-ray and gamma-photon activatable organic compounds, their preparation and their uses |
WO2012021796A2 (en) | 2010-08-12 | 2012-02-16 | S&T Global, Inc. | Novel cyclosporin derivatives for the treatment and prevention of a viral infection |
US20150283272A1 (en) | 2010-10-27 | 2015-10-08 | Vikas Kundra | Dual mode gadolinium nanoparticle contrast agents |
FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
EP2721045B1 (en) | 2011-06-20 | 2017-04-12 | Radiomedix Inc. | Compositions, methods of synthesis and use of carbohydrate targeted agents |
FR2976825B1 (fr) | 2011-06-22 | 2014-02-21 | Total Sa | Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers |
EP2604281B1 (en) | 2011-12-14 | 2014-07-30 | Centre National de la Recherche Scientifique (CNRS) | Clicked somatostatin conjugated analogs for biological applications |
KR20130083592A (ko) | 2012-01-13 | 2013-07-23 | 현대약품 주식회사 | 치환된 피페리딘 유도체 및 이의 제조방법 |
SG11201408150UA (en) | 2012-06-14 | 2015-01-29 | Janssen Biotech Inc | Treatment of pluripotent cells |
CN102743770B (zh) | 2012-06-18 | 2017-07-21 | 申宝忠 | 一种靶向性分子成像探针及活体分子成像方法 |
WO2014037498A2 (en) | 2012-09-07 | 2014-03-13 | Bracco Imaging Spa | Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri. |
WO2014124307A2 (en) | 2013-02-08 | 2014-08-14 | The Regents Of The University Of Michigan | Targeted theranostics |
CN105164136B (zh) | 2013-05-06 | 2017-12-22 | 默克专利股份公司 | 作为激酶抑制剂的大环化合物 |
WO2015023979A1 (en) | 2013-08-16 | 2015-02-19 | Equip, Llc | Discrete peg constructs |
WO2015038968A1 (en) | 2013-09-13 | 2015-03-19 | The General Hospital Corporation | Activatable fibrin-binding probes |
JP2016535013A (ja) | 2013-10-18 | 2016-11-10 | ドイチェス クレブスフォルシュンクスツェントルム | 前立腺特異的膜抗原(psma)の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用 |
EP3077009A4 (en) | 2013-12-03 | 2017-06-14 | The General Hospital Corporation | Molecular imaging probes |
FR3015547B1 (fr) | 2013-12-20 | 2016-01-01 | Total Sa | Methode pour ajuster le taux d'inhibiteurs dans un puits de petrole ou de gaz |
GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
RU2711485C2 (ru) | 2014-04-11 | 2020-01-17 | МЕДИММЬЮН, ЭлЭлСи | Конъюгированные соединения, содержащие сконструированные с цистеином антитела |
AU2015249452B2 (en) | 2014-04-25 | 2017-10-26 | Pfizer Inc. | Antibody-drug conjugates with high drug loading |
EP3142710A4 (en) | 2014-05-16 | 2018-04-25 | Memorial Sloan Kettering Cancer Center | One-step labeling of antibodies to high specific activity with actinium-225 |
WO2016016329A1 (en) | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response |
BE1021191B1 (fr) | 2014-08-29 | 2015-10-27 | Anmi S.A. | Kit pour radiomarquage. |
GB201417067D0 (en) | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
DE102014115154A1 (de) | 2014-10-17 | 2016-04-21 | SCV-SpezialChemikalien-Vertrieb GmbH | Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen |
KR102632418B1 (ko) | 2014-11-25 | 2024-01-31 | 브리스톨-마이어스 스큅 컴퍼니 | 영상화를 위한 신규 pd-l1 결합 폴리펩티드 |
US20190015518A1 (en) | 2016-01-04 | 2019-01-17 | University Of Kansas | Drug delivery compositions and methods |
US10758634B2 (en) | 2016-03-18 | 2020-09-01 | Wake Forest University | Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography |
US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
EP3619191A4 (en) * | 2017-05-05 | 2020-12-16 | Fusion Pharmaceuticals Inc. | PHARMACOKINETIC IMPROVEMENTS OF BIFUNCTIONAL CHELATES AND THEIR USES |
-
2018
- 2018-05-04 AU AU2018261890A patent/AU2018261890A1/en active Pending
- 2018-05-04 BR BR112019023249A patent/BR112019023249A8/pt unknown
- 2018-05-04 RU RU2019139434A patent/RU2019139434A/ru unknown
- 2018-05-04 MA MA049398A patent/MA49398A/fr unknown
- 2018-05-04 CA CA3062538A patent/CA3062538A1/en active Pending
- 2018-05-04 CN CN201880039129.XA patent/CN110891614A/zh active Pending
- 2018-05-04 WO PCT/US2018/031233 patent/WO2018204872A2/en active Application Filing
- 2018-05-04 US US15/971,980 patent/US11433148B2/en active Active
- 2018-05-04 JP JP2020511869A patent/JP7191938B2/ja active Active
- 2018-05-04 EP EP18794036.6A patent/EP3638320A4/en active Pending
- 2018-05-04 KR KR1020197036028A patent/KR20200004861A/ko not_active Application Discontinuation
-
2019
- 2019-11-05 CL CL2019003169A patent/CL2019003169A1/es unknown
- 2019-12-04 ZA ZA2019/08072A patent/ZA201908072B/en unknown
-
2022
- 2022-07-28 US US17/876,272 patent/US20230052140A1/en active Pending
- 2022-12-06 JP JP2022194891A patent/JP2023025209A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1822861A (zh) * | 2003-07-24 | 2006-08-23 | 伯拉考成像股份公司 | 稳定的放射性药物组合物及制备方法 |
US20120213781A1 (en) * | 2011-02-11 | 2012-08-23 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
US20150056191A1 (en) * | 2012-03-30 | 2015-02-26 | Merck Sharp & Dohme Corp. | Igf1 biomarker for igf1r inhibitor therapy |
WO2015073575A2 (en) * | 2013-11-12 | 2015-05-21 | Centre For Probe Development And Commercialization | Residualizing linkers and uses thereof |
Non-Patent Citations (4)
Title |
---|
IRIS VEREL等: "89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies", 《THE JOURNAL OF NUCLEAR MEDICINE》 * |
JEAN CHARLES SORIA等: "A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours", 《J.C. SORIA ET AL. / EUROPEAN JOURNAL OF CANCER》 * |
SANDRA HESKAMP等: "ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model", 《THE JOURNAL OF NUCLEAR MEDICINE》 * |
XIAOYUAN CHEN等: "Integrin αvβ3–Targeted Imaging of Lung Cancer", 《NEOPLASIA》 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018204872A3 (en) | 2018-12-13 |
RU2019139434A (ru) | 2021-06-07 |
JP2020518674A (ja) | 2020-06-25 |
MA49398A (fr) | 2020-04-22 |
JP2023025209A (ja) | 2023-02-21 |
EP3638320A2 (en) | 2020-04-22 |
ZA201908072B (en) | 2023-04-26 |
AU2018261890A1 (en) | 2019-11-28 |
US11433148B2 (en) | 2022-09-06 |
BR112019023249A2 (pt) | 2020-06-02 |
US20230052140A1 (en) | 2023-02-16 |
CL2019003169A1 (es) | 2020-08-14 |
KR20200004861A (ko) | 2020-01-14 |
WO2018204872A2 (en) | 2018-11-08 |
RU2019139434A3 (zh) | 2021-06-17 |
EP3638320A4 (en) | 2021-01-20 |
CA3062538A1 (en) | 2018-11-08 |
BR112019023249A8 (pt) | 2021-02-23 |
US20190083662A1 (en) | 2019-03-21 |
JP7191938B2 (ja) | 2022-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111263747A (zh) | 双官能螯合物的药代动力学增强及其用途 | |
CN110891614A (zh) | Igf-1r单克隆抗体及其用途 | |
CN113474014A (zh) | 放射性免疫缀合物与dna损伤和修复抑制剂组合疗法 | |
CN115243729A (zh) | 大环螯合物及其用途 | |
TW202204336A (zh) | 標靶tem-1之放射免疫結合物及其用途 | |
WO2023122588A2 (en) | Egfr-cmet–targeted compounds and uses thereof | |
WO2023050008A1 (en) | Egfrviii-targeted compounds and uses thereof | |
TW202304532A (zh) | 治療癌症之方法 | |
JP2023518818A (ja) | Fgfr3に標的化されたラジオイムノコンジュゲートおよびその使用 | |
JP2006509744A (ja) | 変化したタンパク質を細胞表面に呈示する腫瘍の診断および処置のための薬剤 | |
WO2023070202A1 (en) | Claudin 18.2-targeted compounds and uses thereof | |
TW202325344A (zh) | 治療癌症之方法 | |
EA045310B1 (ru) | Моноклональные антитела к igf-1r и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200827 Address after: Ontario, Canada Applicant after: CT FOR PROBE DEV AND COMMERCIALIZATION Address before: Ontario, Canada Applicant before: Fusion pharmaceutical Co. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Ari Steven Blake Inventor after: J. R. Forbes Inventor after: M. D. B. Moran Inventor after: R. W. Simms Inventor after: J. F. Varian Inventor after: A. Dawes Inventor before: Ari Steven Blake Inventor before: J. R. Forbes Inventor before: M. D. B. Moran Inventor before: R. W. Simms Inventor before: J. F. Varian |